Paragon 28 (Paragon 28) Change In Receivables : $-3.7 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Paragon 28 Change In Receivables?

Paragon 28's change in receivables for the quarter that ended in Mar. 2024 was $-3.1 Mil. It means Paragon 28's Accounts Receivable increased by $3.1 Mil from Dec. 2023 to Mar. 2024 .

Paragon 28's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.2 Mil. It means Paragon 28's Accounts Receivable increased by $0.2 Mil from Dec. 2022 to Dec. 2023 .

Paragon 28's Accounts Receivable for the quarter that ended in Mar. 2024 was $40.3 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Paragon 28's Days Sales Outstanding for the three months ended in Mar. 2024 was 60.15.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Paragon 28's liquidation value for the three months ended in Mar. 2024 was $-29.6 Mil.

Paragon 28 Change In Receivables Historical Data

The historical data trend for Paragon 28's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paragon 28 Change In Receivables Chart

Paragon 28 Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-5.22

0.39

-6.46

-12.01

-0.16

Paragon 28 Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial												0.44	2.70	0.57	-3.87	-3.10

Paragon 28 Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.7 Mil.

Paragon 28 (NYSE:FNA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Paragon 28's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	40.262	/	61.082	*	91
=	60.15

2. In Ben Graham's calculation of liquidation value, Paragon 28's accounts receivable are only considered to be worth 75% of book value:

Paragon 28's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	58.222	-	170.118	+	0.75 * 40.262	+	0.5 * 104.298
=	-29.6

Paragon 28 Change In Receivables Related Terms

Thank you for viewing the detailed overview of Paragon 28's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Paragon 28 (Paragon 28) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Paragon 28 Inc (NYSE:FNA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

7GQ:Germany

Address

14445 Grasslands Drive, Englewood, CO, USA, 80112

Website

https://www.paragon28.com

Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, charcot, fracture fixation, hallux valgus, hammertoe, and flatfoot.

Executives

Albert Dacosta	director, officer: See Remarks	C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Robert S Mccormack	officer: See Remarks	C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Thomas P Schnettler	director	800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020
Kristina Wright	director	C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
B. Ag Bird	10 percent owner	BAHNHOFSTRASSE 7, ZUG V8 CH-6300
Mvm Partners, Llc	10 percent owner	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Matthew Jarboe	officer: Chief Commercial Officer	C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Partners Llp Mvm	10 percent owner	30 ST. GEORGE STREET, LONDON X0 W1S SFH
Jonathan I Friedman	officer: General Counsel	DENTSPLY SIRONA INC., 30-30 47TH AVENUE, SUITE 500, LONG ISLAND CITY NY 11101
Lee Rosenthal	10 percent owner	C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Quentin S. Blackford	director	7475 LUSK BLVD., SAN DIEGO CA 92121
Frank S. Bono	officer: Chief Technology Officer	5677 AIRLINE ROAD, ARLINGTON TN 38002
Jason Allan Edie	officer: Chief Technology Officer	C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Erik E Mickelson	officer: Chief Accounting Officer	C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Meghan Scanlon	director	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752